雷贝拉唑三联疗法治疗幽门螺杆菌感染相关性胃溃疡的疗效观察

目的观察雷贝拉唑、阿莫西林、克拉霉素三联疗法治疗幽门螺杆菌（Hp）感染相关性胃溃疡的有效性和安全性。方法100例Hp感染相关性胃溃疡患者随机分为治疗组和对照组，治疗组采用雷贝拉唑10mg、2次／d，阿莫西林1．0g、2次／d，克拉霉素500mg、2次／d治疗；对照组采用奥美拉唑20mg、2次／d，阿莫西林1．0g、2次／d，克拉霉素500mg，2次／d治疗。两组疗程均为7d。观察两组临床疗效及Hp根除情况。结果治疗组临床症状疗效总有效率96．0％、溃疡愈合率88．0％、胃镜疗效总有效率94．0％、Hp清除率92．0％、Hp根除率为90．0％，均高于对照组，但两组差异均无统计学意义（均P〉0．05）；两组均未发生严重不良反应。结论雷贝拉唑三联疗法治疗Hp感染相关性胃溃疡有较高的临床效果，且不良反应少。

Effect of rabeprazole-based triple therapy for associated gastric ulcer caused by the helicobacter pylori infection

Objective To evaluate the effects of rabeprazole-based triple therapy for associated gastric ulcer caused by the helicobacter pylori(Hp) infection. Methods 100 patients with associated gastric ulcer caused by the Hp infection were randomly divided into treatment group and control group. The treatment group was given rabeprazole-based triple therapy( rabeprazole 10mg bid, amoxicillin 1.0g bid and clarithromycin 500mg bid), and the control group was given omeprazole-based triple therapy( omeprazole 20mg bid, amoxicillin 1.0g bid and clarithromycin 500mg bid). The two groups were given 7 days treatment. Results The total effective rate of clinical symptoms of treatment group was 96. 0% ,the healing rate of the treatment group was 88.0%, the total effective rate of gastroscopy effect of treatment group was 94.0% ,the Hp clearance rate of treatment group was 92.0% and the Hp eradication rate of treatment group was 90. 0% ,which were higher than the control group,but the difference was not significant( P ＞ 0. 05 ). The two groups had no significant adverse reactions. Conclusion Rabeprazole-based triple therapy for associated gastric ulcer caused by the Hp infection was effective, safe and worth popularization and application.